Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
We evaluated the pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors (NNRTIs) in Ugandan adults. The study design was a three-period crossover study (3 tablets [600 mg of lopinavir/150 mg of ritonavir {600/150 mg}], 4 capsules [533/133 mg], and 2 t...
Main Authors: | Kityo, C, Walker, A, Dickinson, L, Lutwama, F, Kayiwa, J, Ssali, F, Nalumenya, R, Tumukunde, D, Munderi, P, Reid, A, Gilks, C, Gibb, D, Khoo, S |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
2010
|
Títulos similares
-
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
por: Byakika-Kibwika, P, et al.
Publicado: (2012) -
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
por: Gilks, C, et al.
Publicado: (2012) -
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha YJ, et al.
Publicado: (2014-09-01) -
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
por: Musiime, V, et al.
Publicado: (2014) -
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
por: German, P, et al.
Publicado: (2009)